glutamate ionotropic receptor delta type subunit 2Genealiases: GluD2 · SCAR18
Q-omics provides the consensus-scored GRID2 profile across patient tissues and cancer cell-line models. GRID2 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, GRID2 is differentially expressed in 12, with the highest sampling consensus in KIRP. Additionally, GRID2 RNA expression shows 13,228 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCEC, KIRP, and TGCT as cancer lineages where GRID2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GRID2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GRID2 survival associations across molecular data types. GRID2 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GRID2 RNA expression–survival associations across cancer types. High GRID2 expression shows unfavorable associations in UCEC, ESCA, LIHC and MESO, but favorable associations in LGG and KIRC. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for GRID2 RNA expression.
This table summarizes GRID2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for GRID2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GRID2 shows lower tumor expression in KIRP, THCA, COAD, UCEC, KIRC and LUAD. The KIRP box plot shows higher GRID2 RNA expression in normal versus tumor tissue (log2 FC = −0.114, t-test p < 0.001).
This table shows molecular features associated with GRID2 in patient tissues and cancer cell lines. In patient samples, GRID2 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, GRID2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_SCLC and BLOOD_Lymphoma.
